Minerva Neurosciences | NERV - Market Capitalization


Minerva Neurosciences reported $44.3M in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Adma Biologics USD 4.34B 845M Dec/2025
ALKERMES USD 5.53B 909M May/2026
Alterity Therapeutics Limited AUD 40M 16M May/2026
AstraZeneca USD 301.25B 13.1B Mar/2026
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Cipla INR 1.22T 6.47B Dec/2025
Clal Biotechnology ILS 43.45M 8.92M Mar/2026
Compugen USD 144.67M 7.17M Dec/2025
CSL USD 55.89B 20.42B Dec/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Esperion Therapeutics USD 885M 351M Dec/2025
GlaxoSmithKline GBP 83.8B 9.44B Mar/2026
Halozyme Therapeutics USD 7.91B 664M Dec/2025
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
J&J USD 579.15B 78.91B Mar/2026
Merck USD 297.1B 35.84B Mar/2026
Neurocrine Biosciences USD 13.34B 800M May/2026
Novartis USD 232.75B 75B May/2026
Novavax USD 1.09B 316M Dec/2025
Pfizer USD 148.08B 6.51B May/2026
Roche Holding CHF 266.34B 55.46B Dec/2025
Sanofi EUR 100.27B 605.48M Mar/2026
Takeda JPY 7.64T 774.9B Dec/2025
Vanda Pharmaceuticals USD 279M 6M Dec/2024